Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.55 |
| ▸ | HTR2B | P41595 | 6/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22335047 | 0.86 | HTR2C (0.54) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL28829908 | 0.82 | HTR2C (0.56) | HTR2CMAOBKDM1AMAOADRD2 | |
| 4-Phenyl-Butylamine SCHEMBL6684091 | 0.79 | MAOA (0.58) | HTR2CHTR2BHTR2AMAOBMAOA | |
| SCHEMBL22335124 | 0.78 | HTR2C (0.46) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| Benzylamine SCHEMBL7451589 | 0.78 | HTR2C (0.45) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL25262357 | 0.76 | HTR2C (0.59) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL5680153 | 0.76 | HTR2C (0.70) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL17346800 | 0.76 | ESR1 (0.46) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL22341213 | 0.74 | SLC6A2 (0.46) | HTR2A | |
| SCHEMBL18828474 | 0.74 | SLC18A2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056935-B2 | Rotamase enzyme activity inhibitors | GPI NIL HOLDINGS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | GLIAMED, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | FKBP14, FKBP1A, FKBP2 | HTR2C 2018/4885HTR2B 1657/4885HTR2A 1652/4885 |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | HTR2C 3935/4885HTR2B 2996/4885HTR2A 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.